Clinical Trials

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma


Study ID
ECOG-ACRIN EA6134

NCT Number
NCT02224781 (Click on the NCT number for more information about the trial)

Research Study Number
00005996

Principle Investigator
Dr. Donna McNamara

Phase
III

Sponsor
ECOG-ACRIN


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now